Latest Insider Transactions at Resmed Inc (RSMDF)
This section provides a real-time view of insider transactions for Resmed Inc (RSMDF). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RESMED INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RESMED INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 18
2022
|
Michael J. Farrell Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,675
+1.36%
|
$323,475
$57.76 P/Share
|
|
Jan 18
2022
|
Robert Andrew Douglas Special Advisor |
SELL
Open market or private sale
|
Direct |
8,000
-31.78%
|
$1,976,000
$247.8 P/Share
|
|
Jan 18
2022
|
Robert Andrew Douglas Special Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+24.11%
|
$464,000
$58.24 P/Share
|
|
Jan 10
2022
|
Brett Sandercock Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.3%
|
$587,500
$235.0 P/Share
|
|
Jan 10
2022
|
Brett Sandercock Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+2.25%
|
$142,500
$57.76 P/Share
|
|
Jan 03
2022
|
David Pendarvis Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
1,544
-1.31%
|
$398,352
$258.52 P/Share
|
|
Dec 15
2021
|
Michael J. Farrell Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,675
-1.38%
|
$1,447,125
$255.53 P/Share
|
|
Dec 15
2021
|
Michael J. Farrell Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,675
+1.36%
|
$323,475
$57.76 P/Share
|
|
Dec 15
2021
|
Robert Andrew Douglas Special Advisor |
SELL
Open market or private sale
|
Direct |
8,000
-31.78%
|
$2,048,000
$256.52 P/Share
|
|
Dec 15
2021
|
Robert Andrew Douglas Special Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+24.11%
|
$464,000
$58.24 P/Share
|
|
Dec 10
2021
|
Brett Sandercock Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.3%
|
$660,000
$264.92 P/Share
|
|
Dec 10
2021
|
Brett Sandercock Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+2.25%
|
$142,500
$57.76 P/Share
|
|
Dec 03
2021
|
David Pendarvis Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
1,544
-1.3%
|
$396,808
$257.93 P/Share
|
|
Dec 01
2021
|
James Hollingshead President, Sleep Business |
SELL
Open market or private sale
|
Direct |
2,400
-3.03%
|
$614,400
$256.84 P/Share
|
|
Nov 30
2021
|
Michael J. Farrell Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
3,880
+50.0%
|
-
|
|
Nov 30
2021
|
Michael J. Farrell Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
3,880
-43.26%
|
-
|
|
Nov 24
2021
|
Justin Leong Chief Product Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,339
-2.69%
|
$340,106
$254.81 P/Share
|
|
Nov 23
2021
|
Robert Andrew Douglas Special Advisor |
SELL
Bona fide gift
|
Indirect |
791
-0.34%
|
-
|
|
Nov 22
2021
|
Carol Burt Director |
SELL
Open market or private sale
|
Direct |
1,500
-10.28%
|
$390,000
$260.0 P/Share
|
|
Nov 19
2021
|
Michael J. Farrell Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
44,250
-9.84%
|
-
|
|
Nov 18
2021
|
Carol Burt Director |
BUY
Grant, award, or other acquisition
|
Direct |
956
+6.15%
|
-
|
|
Nov 18
2021
|
Ronald R Taylor Director |
BUY
Grant, award, or other acquisition
|
Direct |
956
+4.62%
|
-
|
|
Nov 18
2021
|
Jan De Witte Director |
BUY
Grant, award, or other acquisition
|
Direct |
956
+16.08%
|
-
|
|
Nov 18
2021
|
Harjit Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
956
+13.39%
|
-
|
|
Nov 18
2021
|
Resmed Inc Director |
BUY
Grant, award, or other acquisition
|
Direct |
956
+6.47%
|
-
|
|
Nov 18
2021
|
Peter C Farrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
478
+0.25%
|
-
|
|
Nov 18
2021
|
Karen Drexler Director |
BUY
Grant, award, or other acquisition
|
Direct |
478
+6.02%
|
-
|
|
Nov 18
2021
|
David Pendarvis Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
986
+0.82%
|
-
|
|
Nov 18
2021
|
Robert Andrew Douglas Special Advisor |
BUY
Grant, award, or other acquisition
|
Direct |
2,612
+5.78%
|
-
|
|
Nov 18
2021
|
James Hollingshead President, Sleep Business |
BUY
Grant, award, or other acquisition
|
Direct |
1,709
+1.07%
|
-
|
|
Nov 18
2021
|
Kaushik Ghoshal Chief Commercial Officer, SaaS |
BUY
Grant, award, or other acquisition
|
Direct |
697
+5.87%
|
-
|
|
Nov 18
2021
|
Justin Leong Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
638
+1.25%
|
-
|
|
Nov 18
2021
|
Brett Sandercock Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,161
+1.08%
|
-
|
|
Nov 18
2021
|
Michael J. Farrell Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,469
+0.98%
|
-
|
|
Nov 17
2021
|
David Pendarvis Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,655
-7.56%
|
$2,452,370
$254.81 P/Share
|
|
Nov 17
2021
|
Robert Andrew Douglas Special Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
27,135
-40.45%
|
$6,892,290
$254.81 P/Share
|
|
Nov 17
2021
|
James Hollingshead President, Sleep Business |
SELL
Payment of exercise price or tax liability
|
Direct |
12,060
-13.48%
|
$3,063,240
$254.81 P/Share
|
|
Nov 17
2021
|
Kaushik Ghoshal Chief Commercial Officer, SaaS |
SELL
Payment of exercise price or tax liability
|
Direct |
5,112
-32.8%
|
$1,298,448
$254.81 P/Share
|
|
Nov 17
2021
|
Michael J. Farrell Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,210
-8.66%
|
$10,721,340
$254.81 P/Share
|
|
Nov 16
2021
|
David Pendarvis Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,307
+11.93%
|
$4,395,978
$254.81 P/Share
|
|
Nov 16
2021
|
Robert Andrew Douglas Special Advisor |
BUY
Grant, award, or other acquisition
|
Direct |
45,811
+40.58%
|
$11,635,994
$254.81 P/Share
|
|
Nov 16
2021
|
James Hollingshead President, Sleep Business |
BUY
Grant, award, or other acquisition
|
Direct |
20,360
+18.54%
|
$5,171,440
$254.81 P/Share
|
|
Nov 16
2021
|
Kaushik Ghoshal Chief Commercial Officer, SaaS |
BUY
Grant, award, or other acquisition
|
Direct |
9,162
+37.02%
|
$2,327,148
$254.81 P/Share
|
|
Nov 16
2021
|
Justin Leong Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,162
+15.52%
|
$2,327,148
$254.81 P/Share
|
|
Nov 16
2021
|
Brett Sandercock Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,360
+16.22%
|
$5,171,440
$254.81 P/Share
|
|
Nov 16
2021
|
Michael J. Farrell Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,262
+12.76%
|
$18,100,548
$254.81 P/Share
|
|
Nov 15
2021
|
Carol Burt Director |
SELL
Open market or private sale
|
Direct |
1,187
-100.0%
|
$320,490
$270.8 P/Share
|
|
Nov 15
2021
|
Robert Andrew Douglas Special Advisor |
SELL
Open market or private sale
|
Direct |
8,000
-27.34%
|
$2,168,000
$271.75 P/Share
|
|
Nov 15
2021
|
Robert Andrew Douglas Special Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+21.47%
|
$464,000
$58.24 P/Share
|
|
Nov 11
2021
|
Michael J. Farrell Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,748
-2.06%
|
$2,265,732
$259.47 P/Share
|